Chmiel, P.; Gęca, K.; Rawicz-Pruszyński, K.; Polkowski, W.P.; Skórzewska, M.
FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis? Cells 2022, 11, 3929.
https://doi.org/10.3390/cells11233929
AMA Style
Chmiel P, Gęca K, Rawicz-Pruszyński K, Polkowski WP, Skórzewska M.
FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis? Cells. 2022; 11(23):3929.
https://doi.org/10.3390/cells11233929
Chicago/Turabian Style
Chmiel, Paulina, Katarzyna Gęca, Karol Rawicz-Pruszyński, Wojciech P. Polkowski, and Magdalena Skórzewska.
2022. "FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?" Cells 11, no. 23: 3929.
https://doi.org/10.3390/cells11233929
APA Style
Chmiel, P., Gęca, K., Rawicz-Pruszyński, K., Polkowski, W. P., & Skórzewska, M.
(2022). FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis? Cells, 11(23), 3929.
https://doi.org/10.3390/cells11233929